The severe asthma clinical trial pipeline is robust, featuring over 35 drugs in development by more than 30 pharmaceutical companies. Key players like AstraZeneca, Teva, and Generate Biomedicines are advancing therapies targeting various mechanisms such as thymic stromal lymphopoietin inhibitors and interleukin receptor antagonists. Recent developments include positive Phase II results for verekitug and FDA approval of GSK's Exdensur. This growth reflects rising demand for advanced treatments to address the complex and heterogeneous nature of severe asthma, with multiple drugs in mid to late-stage trials expected to improve patient outcomes.
AstraZeneca PLC will announce its Q2 2026 earnings on July 27, following a strong Q1 with 12.5% revenue growth to $15.29 billion. Key growth driver Enhertu saw a 39.4% year-over-year revenue increase, reaching $831 million, and recently gained EU app...
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
